- Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Yeo YH, Yang JD
- KMID: 2549392
- Clin Mol Hepatol.
- 2024 Jan;30(1):124-125.
- doi: 10.3350/cmh.2023.0470
-
- CITED
-
- Close
- SHARE
-
- Close
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
-
Chang Y, Jeong SW, Jang JY
- KMID: 2549394
- Clin Mol Hepatol.
- 2024 Jan;30(1):129-133.
- doi: 10.3350/cmh.2023.0356
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
-
Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T
- KMID: 2549391
- Clin Mol Hepatol.
- 2024 Jan;30(1):121-123.
- doi: 10.3350/cmh.2023.0437
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Daungsupawong H, Wiwanitkit V
- KMID: 2549388
- Clin Mol Hepatol.
- 2024 Jan;30(1):111-112.
- doi: 10.3350/cmh.2023.0394
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
-
Yew KC, Wong SH, Wong VWS, Oon HH
- KMID: 2549390
- Clin Mol Hepatol.
- 2024 Jan;30(1):118-120.
- doi: 10.3350/cmh.2023.0472
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
-
Yoon EL, Jun DW
- KMID: 2549393
- Clin Mol Hepatol.
- 2024 Jan;30(1):126-128.
- doi: 10.3350/cmh.2023.0500
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”
-
Hsiao C, Liaw YP
- KMID: 2549387
- Clin Mol Hepatol.
- 2024 Jan;30(1):109-110.
- doi: 10.3350/cmh.2023.0373
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
-
Zhang Y, Wu L, Mu Z, Ren L, Chen Y, Liu H, Xu L, Wang Y, Wang Y, Cheng S, Tham YC, Sheng B, Wong TY, Ji H
- KMID: 2549389
- Clin Mol Hepatol.
- 2024 Jan;30(1):113-117.
- doi: 10.3350/cmh.2023.0440
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Correspondence on Letter regarding “Evidencebased hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]
-
Baek SH, Ryu JY, Kim S
- KMID: 2549395
- Clin Mol Hepatol.
- 2024 Jan;30(1):134-134.
- doi: 10.3350/cmh.2023.0261e
-
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in the management of hepatocellular carcinoma
-
Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD
- KMID: 2549380
- Clin Mol Hepatol.
- 2024 Jan;30(1):1-15.
- doi: 10.3350/cmh.2023.0125
Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
-
Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, Hsu YC
- KMID: 2549386
- Clin Mol Hepatol.
- 2024 Jan;30(1):98-108.
- doi: 10.3350/cmh.2023.0194
Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring... -
- CITED
-
- Close
- SHARE
-
- Close
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
-
Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ
- KMID: 2549381
- Clin Mol Hepatol.
- 2024 Jan;30(1):16-36.
- doi: 10.3350/cmh.2023.0315
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
-
Hong H, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Choi J
- KMID: 2549383
- Clin Mol Hepatol.
- 2024 Jan;30(1):49-63.
- doi: 10.3350/cmh.2023.0328
Background/Aims: Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity
-
Ahn S, Jeong SH, Cho EJ, Lee K, Kim G, Kim H
- KMID: 2549382
- Clin Mol Hepatol.
- 2024 Jan;30(1):37-48.
- doi: 10.3350/cmh.2023.0325
Background/Aims: The histological criteria in the 1999 and 2008 scoring systems proposed by the International Autoimmune Hepatitis Group (IAIHG) have their inherent limitations in diagnosing autoimmune hepatitis (AIH). In this... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
-
Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group
- KMID: 2549384
- Clin Mol Hepatol.
- 2024 Jan;30(1):64-79.
- doi: 10.3350/cmh.2023.0287
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to... -
- CITED
-
- Close
- SHARE
-
- Close
- Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
-
Shi Y, Dong H, Sun S, Wu X, Fang J, Zhao J, Han J, Li Z, Wu H, Liu L, Wu W, Tian Y, Yuan G, Fan X, Xu C
- KMID: 2549385
- Clin Mol Hepatol.
- 2024 Jan;30(1):80-97.
- doi: 10.3350/cmh.2023.0343
Background/Aims: To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets. Methods: We conducted Mendelian randomization (MR) to assess the causal role... -
- CITED
-
- Close
- SHARE
-
- Close
